Robinson, Nirmal
Mayo Clinic
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.
Citations 1
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Hong, Lih En , Wechalekar, Mihir D. , Small, Annabelle , Lim, Kelly , Thompson-Peach, Chloe , Li, Joule J., Chhetri, Rakchha , Scott, Hamish S. , Brown, Anna , Hahn, Christopher N , Sajid, Salvia , Robinson, Nirmal , Thomas, Ranjeny , Branford, Susan , D’Andrea, Richard J. , Samaraweera, Saumya E. , Patnaik, Mrinal M. , Hiwase, Devendra , Small, Annabelle , Lim, Kelly , Thompson-Peach, Chloe , Scott, Hamish , Brown, Anna L , Hahn, Christopher , Sajid, Salvia , Robinson, Nirmal , Branford, Susan , D'Andrea, Richard J , Samaraweera, Saumya E , Patnaik, Mrinal , Proudman, Susanna , Kok, Chung H , Shah, Mithun V , Hiwase, Devendra , Kutyna, Monika , Yeung, David , THOMAS, DANIEL W. , Kok, Chung Hoow , Shah, Meera
Blood | March 8, 2024 | Volume: 143 | Issue: 18 | Pages: 1873-1877
Abstract High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.